the Synergistic Compatibility Framework
  • Home
  • What's Inside the Framework
  • SCF Developments
  • SCF Publications
  • SCF Systems Therapeutic’s AI Ecosystem
  • SCF ADVANCED MEDICINE RESEARCH
the Synergistic Compatibility Framework

About the Company

Contact

Regulatory Disclaimer

Terms of Use

SCF GENE-CLASS ATLAS

Document Code: SCF-GCA-MO-0001

Framework Basis: SCF-MULTI-OMIC

Status: Generated atlas draft for preclinical systems-mapping use

1. Purpose

To classify disease-relevant genes into SCF-operational classes using the SCF multi-omic framework so they can be mapped to fault tiers, biomarker panels, therapeutic roles, and translational assay systems. The atlas is anchored in the SCF omics layers of genomics, transcriptomics, epigenomics, proteomics, metabolomics, interactomics, connectomics, and biomechanicalomics, which the framework uses to identify mutation faults, expression collapse, immune tolerance loss, scaffold decay, oxidative imbalance, signal bottlenecks, neural desynchronization, and structural-phase failure.

2. SCF Multi-Omic Gene-Class Logic

The atlas uses five SCF fault domains as the primary organizing spine:

  1. Bioenergetic collapse
  2. ECM scaffold decay
  3. Immune circuit shift
  4. Neural desync
  5. Redox collapse

Each gene class is then evaluated through SCF translational functions:

  • target specificity
  • pharmacokinetic relevance
  • metabolic efficiency relevance
  • resistance-prevention relevance
  • safety relevance

3. Atlas Structure

SCF Gene Class
Primary Omics Anchor
SCF Fault Tier Alignment
Core Biological Function
Example Marker Domain
G1. Genomic Fault Drivers
Genomics
Origin / Tier Initiation
inherited or convergent mutation architecture
SNPs, variants
G2. Transcript Collapse Regulators
Transcriptomics
Tier Propagation
expression suppression, splice dysregulation
RNA-seq, splice maps
G3. Epigenomic Lockout Genes
Epigenomics
Persistence / Immune tolerance drift
methylation and histone-mediated lockout
methylome, chromatin marks
G4. Proteostasis-ECM Scaffold Genes
Proteomics
Structural Tier
scaffold integrity, folding, adhesion
ECM proteins, chaperones
G5. Metabolic Flux Controllers
Metabolomics
Bioenergetic Tier
ATP/cAMP, redox, mitochondrial throughput
ATP:cAMP, NAD+/NADH
G6. Interactome Relay Nodes
Interactomics
Network Bottleneck Tier
PPI relay, signal overload, cross-talk
PPI hubs
G7. Connectomic Rhythm Genes
Connectomics
Neural Timing Tier
vagal/limbic synchrony, circadian output
neural response-linked markers
G8. Biomechanical Response Genes
Biomechanicalomics
Structural-Phase Tier
fascia tension, ECM force sensing, fibrosis
stiffness/integrin-linked markers
G9. Immune Circuit Genes
Multi-omic
Immune Desync Tier
cytokine balance, T-cell state, tolerance
CD4/CD8, IL-2, IL-7, TNF-α, IFN-γ, Treg/Th17
G10. Xenobiotic/Viral Response Genes
Multi-omic
Viragenic / Mutagenic Drift Tier
toxicant-response, proviral-mimetic drift, host hijacking
CYP1A1, CYP1B1, ARNT, proto-oncogene drift metrics

This structure is directly supported by the SCF omics-layered integration model and by the VECTIS-409 assay set, which explicitly names immune, metabolic, ECM-integrin, and AhR-activation panels as core analytical modules.

4. SCF GENE-CLASS ATLAS DETAIL

G1. Genomic Fault Drivers

Definition: Genes whose variants initiate susceptibility, pathway fragility, or convergent mutation faults.

SCF role in atlas: upstream etiopathogenic anchors.

Primary readouts: variant signatures, SNP burden, convergent mutation maps.

G2. Transcript Collapse Regulators

Definition: Genes whose altered transcription or splicing drives expression collapse and downstream loss of pathway fidelity.

SCF role in atlas: dynamic amplifiers of disease-state propagation.

Primary readouts: RNA-seq, splice maps, time-course expression collapse patterns.

G3. Epigenomic Lockout Genes

Definition: Genes controlled by methylation or histone-pattern shifts that produce immune tolerance loss, persistence, and non-responsiveness.

SCF role in atlas: chronicity and relapse-maintenance nodes.

Primary readouts: methylation panels, histone-state profiling.

G4. Proteostasis-ECM Scaffold Genes

Definition: Genes encoding ECM proteins, chaperones, adhesion regulators, and scaffold-maintenance factors.

SCF role in atlas: structural integrity and tissue communication regulators.

Primary readouts: ECM protein maps, chaperone maps, integrin-linked profiles. The SCF fault architecture explicitly links ECM scaffold decay and integrin-phase disruption to fibrosis and tissue miscommunication.

G5. Metabolic Flux Controllers

Definition: Genes governing mitochondrial output, ATP/cAMP coupling, redox control, and energetic reserve.

SCF role in atlas: core bioenergetic control class.

Primary readouts: ATP:cAMP, NAD+/NADH, lactate, mitochondrial ROS. SCF identifies ATP/cAMP exhaustion as a unifying metabolic trigger in multisystemic disease.

G6. Interactome Relay Nodes

Definition: Genes positioned at PPI hubs, relay junctions, and cross-talk bottlenecks.

SCF role in atlas: pathway-routing and system-drift nodes.

Primary readouts: PPI network centrality, relay-node failure, bottleneck stress signatures.

G7. Connectomic Rhythm Genes

Definition: Genes and gene-linked pathways associated with vagal, limbic, circadian, and neuroimmune synchronization.

SCF role in atlas: timing, behavioral, and circuit-fidelity regulators.

Primary readouts: connectomic coupling, circadian-linked transcriptional oscillation, vagal-response signatures. SCF maps neural desync to vagal-cAMP collapse and circadian/behavioral dysfunction.

G8. Biomechanical Response Genes

Definition: Genes involved in mechanotransduction, fascia tension response, ECM strain adaptation, and fibrosis signaling.

SCF role in atlas: structural-phase integrity class.

Primary readouts: fascia strain, ECM tension, stiffness-linked transcription, integrin-phase response. The framework uses biomechanicalomics to locate structural-phase failure such as fibrosis or tissue misfire.

G9. Immune Circuit Genes

Definition: Genes controlling cytokine tone, T-cell state transitions, lymphoid maintenance, and immune synchronization.

SCF role in atlas: inflammatory drift and immune recovery class.

Primary readouts: CD4/CD8, IL-2, IL-7, TNF-α, IFN-γ, Treg/Th17 markers. SCF defines immune circuit shift as a fault domain producing autoimmunity and chronic inflammation.

G10. Xenobiotic/Viral Response Genes

Definition: Genes activated in toxicant sensing, proviral-like hijacking, adaptive stress, and mutagenic drift.

SCF role in atlas: viragenic and xenobiotic convergence class.

Primary readouts: CYP1A1, CYP1B1, ARNT, proto-oncogene drift metrics. In VECTIS-409, these markers define the AhR gene activation profile within the HIV–TCDD convergence program.

5. SCF Fault-Tier Mapping Matrix

SCF Fault Domain
Dominant Gene Classes
Expected Systemic Output
Bioenergetic Collapse
G5, G6, G7
regenerative loss, low reserve, metabolic drift
ECM Scaffold Decay
G4, G8
fibrosis, tissue miscommunication, impaired repair
Immune Circuit Shift
G3, G9, G10
chronic inflammation, immune instability, tolerance collapse
Neural Desync
G7, G9
circadian dysfunction, neuroimmune instability
Redox Collapse
G5, G10
mitochondrial uncoupling, signaling breakdown

This is a direct operationalization of the SCF fault architecture table in the pathophysiology protocol.

6. SCF Therapeutic Relevance Layer

The pathophysiology protocol links these gene classes to therapeutic reconstruction targets:

  • restore cell energy
  • rebuild tissues
  • remove toxic stress
  • balance the immune system
  • re-sync brain-body signals
  • deploy smart delivery

Accordingly, the atlas maps classes to SCF therapeutic roles as follows:

Gene Class
Primary SCF Therapeutic Role
G1
Target-Specific Modulator
G2
Target-Specific Modulator
G3
Safety Harmonizer / Target Modulator
G4
Safety Harmonizer
G5
Metabolic Regulator
G6
Target Modulator / Resistance Prevention support
G7
Metabolic Regulator / Timing Modulator
G8
Safety Harmonizer / Structural Restorative
G9
Target Modulator / Safety Harmonizer
G10
Target Modulator / Resistance Prevention support

These role categories are consistent with the SCF role-assignment framework for target-specific modulators, bioavailability enhancers, metabolic regulators, and safety harmonizers.

7. Atlas-to-Assay Deployment

For preclinical deployment, the atlas can be operationalized through the existing VECTIS-409 assay and modeling system:

Atlas Module
Recommended Assay/Platform
Immune Circuit Gene Module
V409-A11 Fault-Tier Immunogram
Metabolic Flux Gene Module
V409-A12 Mito-Collapse Panel
ECM/Structural Gene Module
V409-A13 ECM-Integrin Disruption Assay
Xenobiotic/Viral Response Gene Module
V409-A14 AhR Gene Activation Profile
Cross-omic simulation
V409-SYS-1 to V409-SYS-4

These assay and modeling modules are already named in the VECTIS-409 identity package and align well with an SCF gene-class atlas implementation path.

8. SCF Synergy Evaluation Layer

Each gene class should be evaluated under the five SCF synergy metrics:

  • TSSM for resistance-prevention durability
  • HSV-F² for metabolic coherence
  • SV-EQ for target specificity
  • MGIS for geometry/PK fit
  • SPCI for safety/tolerance

This means the atlas is not only a classification tool but also a scoring scaffold for candidate APIs, delivery systems, and multi-target stacks.

9. Recommended Standard Output Format for Each Gene-Class Record

For each gene or gene family entered into the atlas, use this minimum record schema:

  • Gene / Gene Family
  • SCF Gene Class
  • Primary Omics Layer
  • Secondary Omics Layers
  • Fault Tier Alignment
  • Mechanistic Role
  • Dominant Biomarker Readouts
  • Relevant Assay Panel
  • Therapeutic Vulnerability
  • SCF Role Assignment
  • PCR Braid Relevance: Preventative / Curative / Restorative
  • SEF Metric Priority: TSSM / HSV-F² / SV-EQ / MGIS / SPCI
  • Regulatory Utility: discovery / preclinical / IND biomarker / clinical stratification

This structure is consistent with the API-discovery requirement for omics breakdown, biomarker panels, ADMET framing, and transition to formulation, synergy matrix, and IND/NDA/BLA pathways.

10. SCF Conclusion

The SCF-MULTI-OMIC framework supports a gene-class atlas organized around cross-omic failure states rather than around isolated genes. In this schema, genes are grouped by their role in mutation initiation, transcript collapse, epigenetic lockout, ECM/proteostasis failure, metabolic breakdown, interactome bottlenecking, neural desynchronization, biomechanical failure, immune-circuit drift, and xenobiotic/viral-response convergence. That architecture is fully compatible with SCF fault mapping, biomarker panel design, synergy scoring, and translational therapeutic engineering.

11. Limitation Statement

Your files provide the SCF multi-omic architecture and assay logic, but they do not provide a canonical, pre-filled list of specific gene symbols for each class. So this atlas is a validated framework-level gene-class model, not yet a disease-specific gene inventory.

12. Next Recommended Expansion

The next rigorous step is to convert this atlas into one of three disease-specific versions:

  1. SCF GENE-CLASS ATLAS — HIV/AEIC
  2. SCF GENE-CLASS ATLAS — TCDD/Xenobiotic Collapse
  3. SCF GENE-CLASS ATLAS — Pan-Regenerative Multi-System Failure

I can build one of those next as a full gene-symbol table with biomarkers, assay mapping, and SCF role assignment.

Master Registry Index: SCF-GCA-MO-0001 | SCF-SEF-MD-0001 | SCF-PP-UVT-0001 | SCF-API-DP-0001 | SCF-CRD-WORKFLOW-0001 | SCF-IDX-V409-PIP-0001